Cargando…

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

The roles of RNA 5-methylcytosine (RNA:m(5)C) and RNA:m(5)C methyltransferases (RCMTs) in lineage-associated chromatin organization and drug response/resistance are unclear. Here we demonstrate that the RCMTs, namely NSUN3 and DNMT2, directly bind hnRNPK, a conserved RNA-binding protein. hnRNPK inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jason X., Chen, Li, Li, Yuan, Cloe, Adam, Yue, Ming, Wei, Jiangbo, Watanabe, Kenneth A., Shammo, Jamile M., Anastasi, John, Shen, Qingxi J., Larson, Richard A., He, Chuan, Le Beau, Michelle M., Vardiman, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862959/
https://www.ncbi.nlm.nih.gov/pubmed/29563491
http://dx.doi.org/10.1038/s41467-018-03513-4
Descripción
Sumario:The roles of RNA 5-methylcytosine (RNA:m(5)C) and RNA:m(5)C methyltransferases (RCMTs) in lineage-associated chromatin organization and drug response/resistance are unclear. Here we demonstrate that the RCMTs, namely NSUN3 and DNMT2, directly bind hnRNPK, a conserved RNA-binding protein. hnRNPK interacts with the lineage-determining transcription factors (TFs), GATA1 and SPI1/PU.1, and with CDK9/P-TEFb to recruit RNA-polymerase-II at nascent RNA, leading to formation of 5-Azacitidine (5-AZA)-sensitive chromatin structure. In contrast, NSUN1 binds BRD4 and RNA-polymerase-II to form an active chromatin structure that is insensitive to 5-AZA, but hypersensitive to the BRD4 inhibitor JQ1 and to the downregulation of NSUN1 by siRNAs. Both 5-AZA-resistant leukaemia cell lines and clinically 5-AZA-resistant myelodysplastic syndrome and acute myeloid leukaemia specimens have a significant increase in RNA:m(5)C and NSUN1-/BRD4-associated active chromatin. This study reveals novel RNA:m(5)C/RCMT-mediated chromatin structures that modulate 5-AZA response/resistance in leukaemia cells, and hence provides a new insight into treatment of leukaemia.